Navigation Links
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Date:6/12/2013

THOUSAND OAKS, Calif., June 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Phase 3 TRINOVA-1 trial evaluating trebananib plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survival (PFS). A statistically significant difference was observed in PFS with a 34 percent reduction in the risk of disease progression or death (HR = 0.66, 95 percent CI, 0.57, 0.77, p<0.001). The median PFS was 7.2 months in the trebananib arm versus 5.4 months in the control arm.

The primary analysis of overall survival (OS), a key secondary endpoint, is expected to mature in 2014 in line with previous guidance. Although an early imbalance of deaths favoring the control arm was observed, there was an overall favorable OS trend for trebananib in a pre-planned interim analysis.

"The TRINOVA-1 study is the first of three Phase 3 trials designed to evaluate the safety and efficacy of trebananib in patients with ovarian cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Angiopoietin inhibition has been a focus of research at Amgen and these results suggest that the novel biology of trebananib may offer a promising approach for patients with ovarian cancer."

In the trebananib arm, the most frequently reported adverse events were localized edema, nausea and alopecia. The rate of discontinuation of investigational product due to adverse events was 20 percent in the trebananib arm versus seven percent in the control arm.

Approximately 22,240 new cases of ovarian cancer will be diagnosed in the United States in 2013.1 More than 70 percent of women with ovarian cancer will present with advanced disease at diagnosis and up to 80 percent of them will exp
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
2. Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting
3. Amgen And Astellas Announce Japan Alliance
4. Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
7. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
8. Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
9. Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
10. Amgens First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
11. Amgen Announces Webcast of 2013 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ ... announced the issuance of a white paper on the ... spray product.  The white paper was presented to the ... by Dr. James H. Anderson, Jr. , MD, ... be viewed online on the Generex website. ...
(Date:8/27/2015)... Aug. 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first ... the United States in a trial ... stent for blockages in the main artery of the leg. ... and potentially less risk for stent fracture or re-narrowing after ... single-arm, multicenter clinical trial of the BioMimics 3D Stent System ...
(Date:8/27/2015)... 27, 2015 According to ... Research titled "Global Market Study on Urinary Catheters: ... 2021", the urinary catheters market is expected to be valued ... It is anticipated to expand at a CAGR ... Mn by 2021. View full report TOC ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4First Pennsylvania Patient Treated in Landmark Vascular Study 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4
... Mobile Dog Heart Health Tour is heading south to ... health examinations in San Antonio,s McAllister Dog Park. From ... veterinary cardiologists will be performing on site heart screenings ... owners about canine heart disease. (Photo: ...
... Celsis In Vitro, Inc. (Celsis IVT) announced today ... District of Illinois in Chicago has entered a preliminary ... (the Defendants) due to their infringement of U.S. Patent ... California (Nasdaq: LIFE ) is the parent ...
Cached Medicine Technology:Free Dog Heart Checks at McAllister Park 2Free Dog Heart Checks at McAllister Park 3Celsis IVT Wins Preliminary Injunction Against Life Technologies and CellzDirect in Liverpool™ Patent Infringement Lawsuit 2Celsis IVT Wins Preliminary Injunction Against Life Technologies and CellzDirect in Liverpool™ Patent Infringement Lawsuit 3
(Date:8/27/2015)... ... August 27, 2015 , ... For the first time, ... with the Nutri Ninja® Auto-iQ Pro Complete and Nutri Ninja Auto-iQ Compact System. ... takes drink customization to a whole new level. This line of Nutri Ninja ...
(Date:8/27/2015)... ... August 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue ... of 2016. The new facility will be located at US Highway 19 North and Highlands ... on August 18, and work on the project is slated to begin in September 2015. ...
(Date:8/27/2015)... ... 27, 2015 , ... King Kullen, America’s First Supermarket, is celebrating 85 years ... in 1930 and recognized by the Smithsonian Institute as America’s First Supermarket, King Kullen ... the Cullen & Kennedy families have created a culture of caring while building their ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since ... has grown to having twelve offices in three counties, LA, Orange and San ... Southern California region. Founded by Dr. Richy Agajanian, the Oncology Institute of ...
(Date:8/27/2015)... ... 27, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that Ms. Esther Sadler-Williams, Global Director Strategic Development and ... Radisson Blu Edwardian Hotel, London Heathrow, on September 9th – 10th, 2015. , ...
Breaking Medicine News(10 mins):Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:King Kullen Honors Their 85 Years of Success this August 2Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2
... ... Medical Chart Conversions to all ePaperless Solutions’ EMR System Clients on the East Coast ... ... -- Scantronix.net, an industry leader in electronic medical record (EMR) scanning, digitization and ...
... Jan. 15 Equinox Holdings, Inc. (the "Company") announced ... eligible purchasers, subject to market and other conditions, of ... 2016 (the "Notes").  The Notes will be guaranteed on a ... future subsidiaries that guarantee the Company,s new revolving credit facility, ...
... ... ( www.PharmaPack-US.com ), a Division of Label-Aire ( www.label-aire.com ) ... Mexico.,PharmaPack packaging machines are manufactured to cGMP specifications and our ... meet customers’ needs. Our product line consists of Unscramblers, ...
... ... of therapy products designed to relieve back pain and neck pain, is set to launch ... , ... 15, 2010 -- Tranquil Touch , LLC is proud to announce the launch of ...
... , ... have partnered to bring the CyberKnife Stereotactic Radiosurgery System to Miami , ... Chicago, IL (PRWEB) January 15, 2010 -- Accelitech ... in partnership with Mercy Hospital in Miami, Florida. , , ,With the launch of the ...
... Highly ... graduate , ... Nexis) January 15, 2010 -- The McGarity Group, a Gwinnett County law firm with special ... Braham has joined the firm as an associate attorney., , ,Braham began her professional ...
Cached Medicine News:Health News:Scantronix and ePaperlessSolutions Form Key Partnership 2Health News:Scantronix and ePaperlessSolutions Form Key Partnership 3Health News:Equinox Holdings, Inc. Commences $400 Million Private Debt Offering 2Health News:New Provider of Tablet/Capsule Packaging Solutions For Offers State-of-the-Art Equipment In The United States & Mexico 2Health News:Tranquil Touch, LLC to Introduce TheraPostion&#8482; at the 2010 Parker Chiropractic Seminar in Las Vegas 2Health News:Tranquil Touch, LLC to Introduce TheraPostion&#8482; at the 2010 Parker Chiropractic Seminar in Las Vegas 3Health News:Anne Marie Braham Joins The McGarity Group as Associate Attorney 2
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Great for small incisions and excision needs...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
2.5mm...
Medicine Products: